TG Therapeutics Inc expected to post a loss of 4 cents a share - Earnings Preview

TG Therapeutics

26/04/2024 15:31

* TG Therapeutics Inc  TGTX.OQ   TGTX.O  is expected to show
a
rise in quarterly revenue when it reports  results on April 29
(estimated) for the period ending March 31 2024
    * The Morrisville North Carolina-based  company is expected
to
report a 599.5% increase in revenue to $54.579 million from $7.8
million a year ago, according to the mean estimate from 7
analysts, based on LSEG data.The company's guidance on January 9
2024, for the period ended March 31, was for revenue between
$41.00 million and $46.00 million.
    * ​LSEG's mean analyst estimate for TG Therapeutics Inc is
for a
loss of 4 cents per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 7 "strong buy" or "buy," 1
"hold" and 1 "sell" or "strong sell."  
    * The mean earnings estimate of analysts had fallen by
about 4.3%
in the last three months. ​
    * Wall Street's median 12-month price target for TG
Therapeutics
Inc is $39.00​, above​ its last closing price of $13.91. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  LSEG IBES  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  ESTIMATE             MET,    SE %
               E®                               MISSED  
 Dec. 31 2023  -0.12       -0.10      -0.10     Met     4.1
 Sep. 30 2023  0.05        0.12       0.73      Beat    530.9
 Jun. 30 2023  -0.24       -0.25      -0.34     Missed  -36.7​
 Mar. 31 2023  -0.38       -0.37      -0.28     Beat    23.7
 ​​Dec.        -0.28       -0.26      -0.39     Missed  -50
 31 2022                                                
 Sep. 30 2022  -0.33       -0.34      -0.26     Beat    23.9​
 Jun. 30 2022  -0.57       -0.51      -0.30     Beat    41.2
 Mar. 31 2022  -0.56       -0.59      -0.51     Beat    14.2
 This summary was machine generated April 26 at 14:31 GMT.  All
figures in US dollars unless otherwise stated. (For questions
concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)